Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
AssigneesThe Regents of the University of California, Genentech, Inc.
InventorsMark X. Sliwkowski, Wolfgang Michael Korn
Life of this patent
Estimating the term…
Abstract
The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and a HER3/EGFR inhibitor (such as MEHD7945A). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
Claims22
A pharmaceutical product comprising (i) GDC-0973 or GDC-0623, or a pharmaceutically acceptable salt thereof;
- and (ii) MEHD7945A for concurrent or sequential use in the treatment of a hyperproliferative disorder.
A pharmaceutical product comprising (i) GDC-0973 or GDC-0623, or a pharmaceutically acceptable salt thereof;
- and (ii) MEHD7945A, as a combined preparation for concurrent or sequential use for improving the quality of life of a patient having a hyperproliferative disorder.
A kit comprising GDC-0973 or GDC-0623, or a pharmaceutically acceptable salt thereof;
- and MEHD7945A, a container, and a package insert or label indicating the administration GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof;
- and MEHD7945A, for treating a hyperproliferative disorder in a patient.
A method for treating a hyperproliferative disorder in a patient, comprising administering to the patient a therapeutically effective amount of (i) GDC-0973 or GDC-0623, or a pharmaceutically acceptable salt thereof;
- and (ii) MEHD7945A.
Dependencies are inferred from the claim text.